Last reviewed 2026-04-22 · How we verify

Adhansia XR

Adhansia XR is a Sympathomimetic amine combined with alpha-2A adrenergic agonist Small molecule drug developed by Purdue Pharma LP. It is currently FDA-approved for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 years and older. Also known as: Methylphenidate hydrochloride (HCl) extended release.

Adhansia XR is a combination of amphetamine salts and guanfacine that increases dopamine and norepinephrine activity while also activating alpha-2A adrenergic receptors to improve attention and reduce hyperactivity and impulsivity.

Adhansia XR is a combination of amphetamine salts and guanfacine that increases dopamine and norepinephrine activity while also activating alpha-2A adrenergic receptors to improve attention and reduce hyperactivity and impulsivity. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 years and older.

At a glance

Mechanism of action

The amphetamine component works as a sympathomimetic amine that increases the release and blocks the reuptake of dopamine and norepinephrine in the central nervous system. The guanfacine component is an alpha-2A adrenergic agonist that enhances prefrontal cortex function and reduces noradrenergic activity in other brain regions. Together, these mechanisms address multiple neurotransmitter systems implicated in ADHD pathophysiology.

Approved indications

• Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 years and older

Common side effects

• Decreased appetite
• Insomnia
• Headache
• Irritability
• Nausea
• Dizziness
• Abdominal pain
• Fatigue

Key clinical trials

• Treating Young Children With Attention Deficit Hyperactivity Disorder (PHASE4)
• AWARE: Management of ADHD in Autism Spectrum Disorder (PHASE4)
• Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits (PHASE4)
• Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children (PHASE4)
• Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) (PHASE4)
• Real World Evidence of the Efficacy and Safety of FOQUEST (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Adhansia XR CI brief — competitive landscape report
• Adhansia XR updates RSS · CI watch RSS
• Purdue Pharma LP portfolio CI

Frequently asked questions about Adhansia XR

Related

• Drug class: All Sympathomimetic amine combined with alpha-2A adrenergic agonist drugs
• Target: All drugs targeting Dopamine transporter, norepinephrine transporter, alpha-2A adrenergic receptor
• Manufacturer: Purdue Pharma LP — full pipeline
• Therapeutic area: All drugs in Neurology / Psychiatry
• Indication: Drugs for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 years and older
• Also known as: Methylphenidate hydrochloride (HCl) extended release

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing